Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
NCT ID: NCT02021097
Last Updated: 2013-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
1008 participants
INTERVENTIONAL
2012-02-29
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LNG100 mcg/EE20 mcg
Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg
Tablet, orally, opd
LNG 150mcg/ EE 30mcg
Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg
Tablet, orally, opd
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg
Tablet, orally, opd
Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg
Tablet, orally, opd
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women without reproductive system infection complications.
* Willingness to not use other forms of hormonal treatment.
* Three regular menstrual cycles before the study(21-35 days per cycle with 3-7 day's bleeding period, without amenorrhea or irregular bleeding).
* Signed informed consent prior to entry into the trial.
Exclusion Criteria
* Vascular, metabolic, hepatic, renal, oncologic and other diseases.
20 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regenex Pharmaceutical, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chengliang Xiong, Dr
Role: PRINCIPAL_INVESTIGATOR
Family Planning Research Institute of TJMC,HUST
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China
Chongqing, Chongqing Municipality, China
Chongqing, Chongqing Municipality, China
Guangzhou, Guangdong, China
Shantou, Guangdong, China
Zhongshan, Guangdong, China
Guiyang, Guizhou, China
Guiyang, Guizhou, China
Wuhan, Hubei, China
Changde, Hunan, China
Changsha, Hunan, China
Nanjing, Jiangsu, China
Nanjing, Jiangsu, China
Yangzhou, Jiangsu, China
Shanghai, Shanghai Municipality, China
Taiyuan, Shanxi, China
Xi’an, Shanxi, China
Tianjin, Tianjin Municipality, China
Ürümqi, Xinjiang, China
Taizhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RH-ZQ-03RCT
Identifier Type: -
Identifier Source: org_study_id